Clinical use of U-500 regular insulin: Review and meta-analysis

Journal of Diabetes Science and Technology

Volumn 6, Issue 2, 2012, Pages 412-420

  Reutrakul, Sirimon ^a   Wroblewski, Kristen ^b   Brown, Rebecca L ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Continuous subcutaneous insulin infusion; Insulin resistance; Multiple daily injections; U 500 regular insulin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; HEMOGLOBIN A1C; HUMULIN R U 500; ISOPHANE INSULIN; METFORMIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

BODY WEIGHT; CONTINUOUS INFUSION; DIABETES MELLITUS; DIABETIC PATIENT; DRUG COST; DRUG FATALITY; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN TREATMENT; MEDICATION ERROR; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PHARMACODYNAMICS; PREGNANCY; PRESCRIPTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN; BLOOD; CHEMICALLY INDUCED DISORDER; COST CONTROL; DRUG EFFECT; ECONOMICS; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; COST SAVINGS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN RESISTANCE; PATIENT SATISFACTION; RISK FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84865135107     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600229     Document Type: Review

References (41)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-3.
2. The efect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14)977-86.
3. Dolberg BK, Lenhard MJ. Successful outcome of pregnancy in a patient with generalized lipoatrophic diabetes mellitus. Endocr Pract. 2000;6(1):34-6.
4. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore). 2002;81(2):87-100. (Pubitemid 34218566)
5. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, Roth J. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976;294(14):739-45.
6. Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004;83(4):209-22. (Pubitemid 38955444)
7. Crasto W, Jarvis J, Hackett E, Nayyar V, McNally PG, Davies MJ, Lawrence IG. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad Med J. 2009;85(1002):219-22.
8. Dailey AM, Tannock LR. Extreme Insulin Resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus. Curr Diab Rep. 2011;11(2):77-82.
9. Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB, Skyler JS. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15(1):71-9.
10. Binder C. Absorption of injected insulin. A clinical-pharmacological study. Acta Pharmacol Toxicol (Copenh). 1969;27 Suppl 2:1-84.
11. Gagnon-Auger M, du Souich P, Baillargeon JP, Martin E, Brassard P, Ménard J, Ardilouze JL. Dose-dependent delay of the hypoglycemic efect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. Diabetes Care. 2010;33(12):2502-7.
12. Segal AR, Brunner JE, Burch FT, Jackson JA. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm. 2010;67(18):1526-35.
13. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7(2):188-99. (Pubitemid 14137203)
14. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981;4(3):366-76. (Pubitemid 12201586)
15. Khan M, Lee YY. The pharmacokinetic and pharmacodynamic properties of regular U-500 insulin in healthy non-obese subjects. (Abstract). Diabetes. 2007;569(suppl):P-1294.
16. Khan M, Sarabu B. The pharmacokinetics and pharmacodynamic properties of regular U-500 insulin in healthy obese subjects (Abstract). Diabetes. 2009;58(suppl):PO-2333.
17. Davidson MB, Navar MD, Echeverry D, Duran P. U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care. 2010;33(2):281-3.
18. De la Peña A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, Win KM, Hompesch M, Mace KF, Jacobson JG, Jackson JA. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34(12):2496-501. Epub 2011 Oct 12.
19. Ballani P, Tran MT, Navar MD, Davidson MB. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care. 2006;29(11):2504-5. (Pubitemid 44912260)
20. Wafa WS, Khan MI. Use of U-500 regular insulin in type 2 diabetes. Diabetes Care. 2006;29(9):2175-6. (Pubitemid 44871206)
21. Nayyar V, Lawrence IG, Kong MF, Gallagher A., Gregory R, Hiles S, Jackson S, McNally P, Davies MJ. Long-term follow-up of patients on U-500 Human Actrapid. (Abstract). Diabetologia. 2007;50(Suppl 1):S538.
22. Neal JM. Analysis of efectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy. Endocr Pract. 2005;11(5):305-7.
23. Dailey AM, Williams S, Taneja D, Tannock LR. Clinical eficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract. 2010;88(3):259-64. Epub 2010 Mar 11.
24. Garg R, Lawrence IG, Akinsola M.O., Davies MJ, McNally PG. Improved glycaemic control in severely insulin resistant, insulin treated diabetic patients with U500 Human Actrapid over two year follow-up. (Abstract). Diabetologia. 2004;47(Suppl 1):A58.
25. Boldo A, Comi RJ. Clinical Experience with U-500 Insulin: Risks and Benefits. Endocr Pract. 2011;1-17. [Epub ahead of print]
26. Quinn SL, Lansang MC, Mina D. Safety and efectiveness of U-500 insulin therapy in patients with insulin-resistant type 2 diabetes mellitus. Pharmacotherapy. 2011;31(7):695-702.
27. Ziesmer AE, Kelly KC, Guerra PA, George KG, Dunn FL. U-500 Regular Insulin Use In Insulin Resistant Type 2 Diabetic Veteran Patients. Endocr Pract. 2011;1-15. [Epub ahead of print]
28. Lane WS. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract. 2006;12(3):251-6.
29. Bulchandani DG, Konrady T, Hamburg MS. Clinical eficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr Pract. 2007;13(7):721-5.
30. Lane WS, Weinrib SL, Rappaport JM, Przestrzelski T. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. Endocr Pract. 2010;16(5):778-84.
31. Knee TS, Seidensticker DF, Walton JL, Solberg LM, Lasseter DH. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract. 2003;9(3):181-6.
32. Schwartz FL. A caution regarding U-500 insulin by continuous subcutaneous infusion. Endocr Pract. 2004;10(2):163-4.
33. Reutrakul S, Brown RL, Koh CK, Hor TK, Baldwin D. Use of U-500 regular insulin via continuous subcutaneous insulin infusion: clinical practice experience. J Diabetes Sci Technol. 2011;5(4):1025-6.
34. Hatipoglu B, Soni S, Espinosa V. Glycemic control with continuous subcutaneous insulin infusion with use of U-500 insulin in a pregnant patient. Endocr Pract. 2006;12(5):542-4. (Pubitemid 46456042)
35. Wong VW, Pape AV. Extreme insulin resistance in a patient with pre-existing diabetes during pregnancy: role of U-500 insulin. Med J Aust. 2009;190(11):650-1.
36. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28(5):1240-4. (Pubitemid 40616647)
37. Lane W, Weinrib S, Rappaport J. The efect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther. 2011;13(5):592-5. Epub 2011 Mar 15.
38. Humulin R (insulin human [rDNA origin] injection), U-500. Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) March 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm250517.htm. Accessed January 12, 2012.
39. U.S. Food and Drug Administration. MAUDE Adverse Event Report. U.S. Department of Health and Human Services. http://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi-ID=1912699. Accessed January 12, 2012.
40. Deal EN, Tobin GS. Policy implementation for inpatient management of U-500 insulin resulting in lower incidence of hypoglycemia. Endocr Pract. 2011;17(3):521.
41. Samaan KH, Dahlke M, Stover J. Addressing safety concerns about U-500 insulin in a hospital setting. Am J Health Syst Pharm. 2011;68(1):63-8.